Ameriprise
FLXN

Ameriprise’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Ameriprise’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-46,282
Closed -$1.25M – 3816
2017
Q1 		$1.25M Buy
+46,282
New +$945K ﹤0.01% 2794

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Ameriprise's FLXN Position: Q2 2017 in Review

Ameriprise sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2017, closing a stake of 46,282 shares — an estimated $1.25M sold.

Ameriprise first reported a position in FLXN in Q1 2017 and held it in 1 quarter. The position peaked at $1.25M in Q1 2017. 100 funds tracked by Wall St. Rank hold FLXN as of Q2 2017.

  • Ameriprise reported no remaining Flexion Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Ameriprise sold 46,282 Flexion Therapeutics, Inc. shares in Q2 2017, an estimated $1.25M.
  • Ameriprise first reported a position in Flexion Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Ameriprise's Flexion Therapeutics, Inc. position peaked at $1.25M in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2017.

Based on Ameriprise's 13F filing for Q2 2017, filed 10 Aug 2017.